Scientists have achieved a breakthrough in targeted protein degradation by identifying a new class of "molecular glues" through an unprecedented large-scale screening of cells, opening doors to novel therapies for diseases like cancer and neurodegeneration. Researchers at the Broad Institute and collaborators sifted through millions of chemical compounds in live human cells, pinpointing molecules that hijack the cell's natural protein disposal machinery to selectively dismantle disease-causing proteins.
The study, published in Nature, employed a high-throughput assay where cells were engineered with fluorescent reporters linked to specific target proteins. When a molecular glue binds, it bridges the target protein to an E3 ubiquitin ligase, triggering ubiquitination and subsequent destruction by the proteasome. From over 5 million compounds screened, the team isolated dozens of potent glues, several of which demonstrated sub-nanomolar potency against therapeutically relevant targets such as BRD4, a protein implicated in various cancers.
Unlike bulkier PROTACs—bifunctional degraders that have dominated the field—these molecular glues are smaller, more drug-like molecules capable of penetrating cells more efficiently and potentially being administered orally. Lead researcher Nathanael Gray highlighted their elegance: "These glues don't just inhibit proteins; they erase them entirely, resetting cellular homeostasis in ways traditional drugs can't achieve." The discovery validates a long-hypothesized approach, building on natural examples like thalidomide, which inadvertently acts as a glue.
The screening's scale and cellular context mark a shift from in vitro hits to biologically validated degraders, addressing past pitfalls where promising candidates failed in living systems. Early validation in mouse models showed tumor regression without overt toxicity, fueling optimism for clinical translation. However, challenges remain, including off-target degradation risks and the need for patient-specific glues.
Industry experts view this as a pivotal moment for the burgeoning field of induced proximity therapeutics, now valued at billions in venture funding. Companies like Arvinas and C4 Therapeutics are racing to adapt similar platforms, while Big Pharma scouts talent and IP. As one biotech analyst noted, "This isn't just science—it's a paradigm shift that could render many kinase inhibitors obsolete."
Looking ahead, the researchers plan to expand the screen to additional E3 ligases and disease targets, including tau in Alzheimer's. With regulatory pathways clarifying for degraders, these molecular glues could reach trials within years, promising a new era where undruggable proteins become vulnerable to chemical annihilation.
